VIDEO: ALINA study could be ‘paradigm-shifting’ for ALK-positive NSCLC
Click Here to Manage Email Alerts
MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung cancer, which were presented at ESMO Congress, in a video interview with Healio.
The phase 3, randomized study, which compared alectinib (Alecensa, Genentech) and platinum-based chemotherapy in patients with ALK-positive NSCLC, demonstrated that “the disease-free survival favored the use of alectinib in this setting,” according to Borghaei, chief of the division of thoracic medical oncology at Fox Chase Cancer Center.
“This becomes the second targeted therapy that now we have access to for early-stage disease,” Borghaei said. “This is the kind of study that can be paradigm-shifting and changing standard practice as soon as regulatory approval is obtained because, again, we definitely see these patients in our clinics, so I think it’s important to keep track of this.”
Reference:
- Solomon B, et al. Abstract LBA2. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts